Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
Date:1/29/2008

NEW YORK, Jan. 29 /PRNewswire/ -- QED International Associates, Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Thursday January 31, 2008 KV Pharmaceutical Company (NYSE: KV-A) will replace Adams Respiratory Therapeutics (Nasdaq: ARXT) in the HealthShares(TM) Composite Index. Watson Pharmaceuticals Inc. (NYSE: WPI) will also replace Adams Respiratory Therapeutics in the HealthShares(TM) Respiratory/Pulmonary Index. Adams Respiratory Therapeutics is being acquired by Reckitt Benckiser Group PLC (London Stock Exchange: RB.L)

The HealthShares(TM) Composite Index consists of the 80 largest companies by market capitalization that are engaged in healthcare, life sciences and/or biotechnology that are part of the 20 Composite eligible Indexes.

Companies included in the HealthShares(TM) Respiratory/Pulmonary Index are engaged in the research, development, and/or commercialization of therapeutic agents treating various respiratory and/or pulmonary diseases including, but not limited to, asthma, chronic obstructive pulmonary disease, emphysema, tuberculosis and pulmonary arterial hypertension.

About QED International Associates

QED International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com


'/>"/>
SOURCE QED International Associates, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rice wins innovation award for international program
2. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
3. For creating new field of science, Texas chemist wins international prize
4. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
5. Tasker Products to Showcase Tasker Blue at International Poultry Expo
6. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
7. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
8. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
9. Carbon offset warning from international team of scientists
10. Palomar and Q-MED AB Enter Into International Distribution Agreement
11. International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... PHOENIX and NEW YORK ... announced the near completion of their $7M Series B ... on top of the $3.5M led by Mesa Verde ... of 2016.  These resources will be directed towards further ... Test, PCDx, a comprehensive genomic profiling test and expanding ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):